 Clin. Invest. 1992. 90:412-420.)
Introduction
To apply greater control over typhoid fever, which currently results in about 30 million cases and 500,000 deaths each year ( 1 ), the World Health Organization has given a high priority to the improvement of vaccines against Salmonella typhi (2) . The development of a safe but highly immunogenic live oral typhoid vaccine for use in such programs would have advantages over the currently available reactogenic whole-cell parenteral typhoid vaccines and the well-tolerated but modestly immunogenic live oral typhoid vaccine strain Ty2 la (3) (4) (5) . In addition, a highly immunogenic live oral typhoid vaccine would ideally be suited as a carrier ofgenes that express protec-tive antigens, cloned from other pathogens (6) (7) (8) (9) . Such hybrid recombinant Salmonella vaccines are expected to invoke protective immunity in humans against both the carrier strain as well as the foreign antigen.
In the 1950s, Bacon and co-workers (10) showed that a p-aminobenzoic acid (PABA)'-dependent strain of S. typhi was attenuated in mice (10) . This work did not receive much attention until recently when Hoiseth and Stocker ( 11 ) showed that an aroA mutant of Salmonella typhimurium, dependent on aromatic amino acids, PABA, and 2,3-dihydroxybenzoate (DHB; restores ability to synthesize the iron chelator enterochelin) for growth, was attenuated but immunogenic in mice.
Building on this earlier observation, Edwards and Stocker (12) carefully constructed a nonreverting aromatic-dependent mutant (aroA) of S. typhi strain CDC . Because there exists a very remote chance that a single mutation can be lost and the wild-type allele restored as a result of in vivo DNA exchange with other organisms, a nonreverting purA deletion mutation (causing adenine or adenosine dependence) was introduced into their aromatic-dependent derivative for added safety ( 12) . In clinical trials two such S. typhi aroA purA strains were remarkably well tolerated by volunteers and elicited cellmediated immunity in nearly all volunteers (4) . Unfortunately, S. typhi aroA purA strains induced only meager humoral responses in a small percentage ofvolunteers even when two 109-organism doses were given (4) . The noneffectiveness of the S. typhi aroA, purA mutants suggests that S. typhi mutants with only a single auxotrophic requirement should be evaluated as live oral typhoid vaccines.
There are data showing that aro mutants ofSalmonella are attenuated in animals but retain high levels ofimmunogenicity (1 1, 13-18) . This finding, taken together with a study of S. typhimurium auxotrophic mutants in mice showing that the purA mutation either alone or in combination with aroA results in poorly immunogenic vaccine strains ( 15, 18) , suggests that evaluation ofS. typhi aro mutants is a direction ofchoice. The aro genes are well separated on the Salmonella chromosome ( 19) and several individual aro genes have been shown to be equally attenuating ( 12, (20) (21) (22) .
Methods
Bacterial strain and media Strain CVD 906, a derivative ofwild-type S. typhi ISP1820, carries two well-separated, genetically well-defined aro mutations, AaroC 1019 and AaroD 1013 (22) . Strains ISP1820 (09, 12 ; Vi+, phage type 46; HA) and CVD 906 (09, 12; Vi+; HA) were grown at 37°C aerobically on Aro-agar, which includes 0.5% (wt/ vol) yeast extract (Difco Labora-tories, Inc., Detroit MI), 1% (wt/vol) Bacto-tryptone (Difco Laboratories, Inc.), 1.5% Bacto-agar (Difco Laboratories, Inc.), 0.5% NaCi (Sigma Chemical Co., St Louis, MO), 0.2% (wt/vol) casamino acids (Difco Laboratories, Inc.), 0.25% (wt/vol) glucose (Sigma Chemical Co.), 73 mM PABA, 73 mM DHB (Sigma Chemical Co.), and 100 Ag/ml ferric ammonium citrate (Sigma Chemical Co.), which maximized the growth ofCVD906 relative to ISP1820. Liquid cultures were grown at 370C with shaking for 16 h in Aro-broth which is Aro-agar without the addition of Bacto-agar. Strains were stored in storage medium consisting of an equal volume mixture of 100% (vol/vol) glycerol and Aro-broth at -850C.
Growth in human serum
Pooled normal human sera (Gibco, Grand Island, NY) was tested for S. typhi-specific antibody by enzyme-linked immunosorbent assays (ELISA) using S. typhi lipopolysaccharide (LPS) or formalin-inactivated S. typhi Ty2 cells as antigens (4) . Serum substantially free of antibody specific for S. typhi, was heat inactivated at 560C for 1 h. To triplicate 2-ml aliquots of serum, S. typhi bacilli, grown in 0.8% (wt/ vol) Nutrient broth (Difco, Inc.) at 370C anaerobically, suspended in 10 ,d ofN-saline (0.9% wt/vol NaCl) were added at a starting viability of 50 colony-forming units (cfu)/ml. Immediately a sample was taken and spread onto Aro-agar and incubated at 370C for 18 h. The remaining serum/cell suspension was placed at 370C. Then at 3,6,9, and 24 h after inoculation additional samples were taken and viable counts were determined. Results are expressed as the logl0 of the arithmetic mean cfu/ml of each triplicate±2 SD versus time in hours.
Growth in U937 cells
Human histiocytic lymphoma cell line U937 was cultured in RPMI 1640 (Gibco) supplemented with 10% (vol/vol) fetal calf serum (Gibco) as described (23) . U937 cells cultured without antibiotics were stimulated with phorbal myristate acetate (PMA, Sigma Chemical Co.) at a final concentration of6 ng/ml for 3 d before infection and allowed to differentiate into adherent macrophage-like cells (23) . Microscopic examination of U937 cells 3 d after PMA induction revealed high levels of intracellular vacuolation. Each well of a 96-well tray contained -106 adherent U937 cells. Liquid cultures ofS. typhi were grown in Aro-broth at 370C with shaking to about 4 X 10 cfu/ml. The bacterial cells were harvested by centrifugation then washed three times in the U937 culture medium. Dilutions ofthe bacterial cell suspensions were added to U937-containing culture wells such that the multiplicity of infection was two bacteria per U937 cell. Triplicates for each strain for each time point were cultured in parallel. After addition of the bacteria the plates were centrifuged at 250 g for 5 min to bring more bacteria in close contact with the U937 cells and enhance the numbers of bacteria phagocytosed (24) . After 1 h at 37°C gentamicin (Sigma Chemical Co.) was added at a final concentration of 200 ug/ml to inactivate extracellular bacteria (24) . After 1 h at 370C with this high level ofgentamicin, the cells were washed four times in culture medium and then maintained for the remaining time of the experiment with gentamicin at 10 gg/ml and incubated at 37°C/5% CO2. Samples were taken at the time of, and 1 (0-h time point), 9 (8 h), and 25 (24 h 350C . About four single colonies were suspended in ice-chilled phosphate-buffered saline (PBS) then placed on ice. A sample of this suspension was serotyped. The optical density at 660 nm (OD6w) of the remaining suspension was measured and the viability was estimated based on previously determined correlation between the viability and the OD6w of a given suspension ofCVD 906. The suspension then was diluted such that 1 ml of the bacterial suspension contained a single inoculum. Dilutions of the final suspension were spread onto Aro-Agar for direct determination of the viable count and purity of the inocula.
Clinical microbiological techniques
All stool samples taken after vaccination were weighed and graded as described (4) . Rectal swabs were taken ifa volunteer failed to produce a stool in the previous 24 h. Quantitative and qualitative bacteriological screening methods of stool samples were as described (4) . Biotyping and serotyping of CVD 906 and clinical isolates were performed as described (4) . Gelatin-encapsulated string devices for collecting duodenal fluid containing bile were used as described on days 6, 9, and 13 after vaccination (4) . Blood cultures were taken promptly from volunteers who developed temperatures > 38.20C. In addition, routine blood cultures (5 ml) were collected on days 5, 8, 12, and 15 after vaccination. Blood culture methods were as described (4) .
Volunteers
The 20 volunteers who participated in the clinical evaluation of strain CVD 906, 9 who ingested 5 X I0', and 11 who ingested 5 x I03, were healthy adults, 18-33 yr ofage, with no prior history oftyphoid fever or typhoid vaccination. They were recruited from the metropolitan Baltimore community and admitted to the isolation ward of the Center for Vaccine Development for 20 d. Preclinical screening and informed consent was obtained from each volunteer (4).
Vaccination and clinical surveilance
The candidate vaccine strain CVD 906 was administered by the oral route. The volunteers were allowed to acclimatize in the isolation ward for a 48-h period before vaccination and refrained from eating for 90 min before immunization. To neutralize the gastric acid ofeach volunteer, 2 g of NaHCO3 were dissolved in 150 ml of sterile distilled water (pH 8.15), and each volunteer ingested 120 ml of the bicarbonate solution. 1 min later, each volunteer ingested the remaining 30 ml of bicarbonate solution mixed with the appropriate inoculum dose ofthe candidate vaccine strain CVD 906 (mixed no more than 10 min before vaccination). The viability of CVD 906 was not affected when CVD 906 was suspended in this bicarbonate solution for up to 30 min at room temperature (data not shown). The volunteers remained without food and water for 90 min after ingestion of the inoculum dose.
Clinical surveillance was performed as described (4) . The volunteers were interviewed daily after vaccination to determine whether such side effects as fevers, chills, headache, malaise, or diarrhea were experienced. Temperatures, measured orally, were taken at 6-h intervals for 20 d after vaccination. If a volunteer developed culture-confirmed bacteremia or if their temperature remained elevated > 38.2°C for > 48 h, then treatment with oral amoxicillin (a first dose of 1.5 g, then 1 g every 6 h for 14 d) was begun. Ciprofloxacin (500 mg every 12 h for 14 d) was given to all volunteers begining on day 12 after vaccination.
Immunological methods
Sample collecting and processing. Blood samples for serology were collected before and on days 7, 21, and 28 after vaccination. Approximately 70 ml ofjejunal fluid was collected and processed before and 15 d after vaccination by upper intestinal intubation as described (4) . Total IgA in the jejunal fluids was measured by ELISA and each specimen was standardized to contain 20 mg of IgA per 100 ml ofjejunal fluid (4). PBMC were obtained before and 4, 7, 10, and 14 d after vaccination by centrifugation of -30 ml of venous blood on FicollHypaque (Organo Teknika, Durham, NC) and processed as described to a final working concentration of 107 PBL/ml (25) .
Antigen preparation. S. typhi LPS was from Difco Laboratories. Vi polysaccharide was purified from S. typhi by the method of Wong and Feeley (26) . H-d flagella antigen was prepared from S. typhi strain 514Ty ( 12) as described (27) .
Serology. IgG, IgM, and IgA immune responses in sera were measured to S. typhi LPS, and Vi by ELISAs (4). Net optical densities at 405 nm (OD405) were measured by the differences obtained in serum samples binding to wells coated with antigen minus the OD405 in wells containing sera binding to wells coated only with buffer. Significant LPS-specific IgG seroresponse were defined as those sera that produced a change in net OD405 2 0.2 (from pre-to post-samples) at a 1:100 dilution. All other antibody class-specific LPS or Vi responses were considered significant if fourfold rises in titer (from pre-to postvaccination samples) were detected using twofold dilutions of sera starting at 1:25. End points were determined using 0.1 as the net OD405 cutoff for LPS-, whole cell-, and H-d antigen-specific serum responses. The net OD405 cutoffs for Vi antigen-specific serum responses were 0.2 for IgG, 0.15 for IgA, and 0.3 for IgM.
Widal assays were performed to detect flagella agglutinating antibodies using S. virginia (expresses H-d flagella) as antigen (4) . Also, an ELISA was developed for the evaluation of S. typhi H-d-specific antibodies. Cooke polystyrene "U" bottom 96-well plates were coated with 5 Ag/ml antigen in carbonate buffer (pH 8.0) alternating with negative control noncoated wells. Optimal coating concentration was determined by checkerboard titration using a high titered pooled widal-positive (using S. virginia H-d+ as the agglutinating antigen) serum specimen. After washing with PBS containing 5% Tween 20 (PBS-Tween), pH 7.2, plates were blocked with PBS 5% fetal bovine serum for 1 h at room temperature. Serum specimens then were added at twofold dilutions starting at 1:25 and incubated at 37°C for 1 h. After washing and , 38_ 0 h.3 incubating with the appropriate conjugate, the assay was developed with substrate and the plates were read after 30 min. The end-point titration OD405 level was determined by using pooled sera from a negative control population of 30 U.S. volunteers. The mean net OD405 of these control sera + 2 SD above the mean was used as the cutoff net OD405; a serum dilution with an OD340 value below the cutoff OD405 was considered not to contain antibody. A fourfold rise in titer from pre-to postsera ofthe typhoid vaccination study group was considered significant.
Intestinal secretory IgA antibodies to LPS, H, and Vi antigens were measured by ELISA (4). Fourfold or greater rises in titer were considered significant.
Detection ofantibody-secreting cells (ASCs). PBMC were used for the detection of S. typhi LPS-, HA-, and Vi-specific IgG, IgM, and IgA ASC responses by ELISPOT (25 (Fig. 1 ). This volunteer also experienced abdominal discomfort and a headache but recovered without antibiotic intervention from these early symptoms. On days 7-9 the volunteer reported abdominal discomfort without accompanying headache or malaise and remained afebrile. Again the abdominal symptoms subsided without therapeutic intervention but the abdominal symptoms recurred on day 12 for a further 3 d. This volunteer was treated with ciprofloxacin on day 12 after vaccination. The other febrile reaction began on day 4, when volunteer 13001-1 (87.3-kg male) developed an oral temperature of 38.60C. The temperature of the volunteer briefly subsided before increasing to a peak of 39.50C (Fig. 1) . This febrile volunteer also experienced a headache, nausea, abdominal discomfort, and cough but showed no evidence of toxemia or significant malaise. Antibiotic therapy was initiated 24 h after onset of this symptom complex after which the volunteer's elevated oral temperature and other symptoms gradually abated ( Fig. 1) . None of the volunteers in this cohort experienced diarrhea during the course of the study. All duodenal string cultures from volunteers in the high dose cohort, performed on days 6, 9, and 13 after vaccination, were negative for CVD 906 bacilli.
After ingestion of 5 x 101 CVD 906 bacilli, none of the volunteers excreted detectable CVD 906 bacilli, none of the volunteers experienced diarrhea, and no duodenal string cultures was positive in this group.
Blood cultures. The volunteer who became febrile on day 4 after vaccination was blood culture positive for CVD 906 bacilli at the time of the febrile episode and remained blood culture positive until day 7 (Fig. 1) . Also, four afebrile volunteers produced positive blood cultures on day 7 after vaccination.
One of this group of afebrile, blood culture-positive volunteers produced a second positive blood culture containing CVD 906 bacilli on day 10 after vaccination. Blood isolates of CVD 906 from the volunteers were stored at -85°C. The blood isolates displayed no measurable changes in aromatic growth factor requirements, serotype, and biotype, as compared to that ofthe parental strain CVD 906.
SEROLOGY
The majority ofvolunteers vaccinated with 5 X 10' cfu ofCVD 906 manifested highly significant serum humoral responses specific for S. typhi LPS and H-d antigen (Table I) . Also Widalpositive sera were found in six of the nine volunteers in this cohort (66.7%; Table I ). No significant rises in serum antibody specific for Vi antigen were detected (data not shown).
As evidence ofintestinal immunopriming, impressive IgGsecreting as well as IgA-secreting ASC responses specific for either LPS or H-d flagella antigen developed in 89% of this high-dose cohort (Table II) . Highly significant elevations of IgM-secreting ASC specific for S. typhi LPS antigen and IgMsecreting ASC specific for H-d flagella antigen were found in 78% and 89% of this high-dose group respectively (data not Some of the volunteers in the low-dose cohort developed rises in peripheral blood ASC specific for S. typhi LPS antigen and H-d flagella antigen after vaccination with 5 x I03 cfu of CVD 906 (Table III) .
Growth in human serum Strain CVD 906 grew for about nine generations in pooled human serum whereas parent strain ISP1820 grew through many more generations in pooled human sera (Fig. 2) . Adding PABA to human serum at a final concentration of 5 Growth in U937 human macrophages
The growth of ISP1820 and CVD 906 in U937 cells is shown (Fig. 3) 
Discussion
The shortfall of other attenuated S. typhi strains 27V, Ty2 Ia, and 54 lTy (aroA purA) is their variable or poor immunogenicity (4, 5, 28, 29) . However, these strains are remarkably safe such that even after volunteers ingest as many as 1010 viable 27V, Ty2 la, or 541Ty bacilli no significant side reactions are observed (4, 28, 29) . Clearly, new candidate typhoid vaccines will be judged against this background and will not be considered advantageous over these existing strains unless they achieve similar safety in humans but with greatly enhanced immunogenicity.
A single dose of 5 x 101 CVD 906 bacilli meets this criterion. In placebo-controlled field trials the rate of IgG seroconversion to S. typhi LPS among Chileans correlates with protection (28). If (32) . We conclude that CVD 906 is considerably attenuated. A more precise measurement of the attenuating effect of the aro mutation will require the evaluation of a double aro mutant ofa wild-type S. typhi strain that has a well-documented virulence in humans.
Dragunsky et al. (33) reported that S. typhi strains Ty2Ia and 54 lTy (aroA purA) with documented safety in humans are incapable of intracellular growth in U937 monocytes, whereas a galE Vi-negative strain, EX462, that retains some virulence for humans underwent limited growth in these monocytes. Thus, the capacity to grow in U937 monocytes correlates with the documented clinical tolerance of these strains in volunteers. We demonstrated that CVD 906 retains some capacity to grow inside phorbol myristate acetate-induced U937 human macrophage-like cells. Intracellular growth by CVD 906, wherein CVD 906 mainly resides during vaccination, might in part contribute to the occasional adverse clinical reactions in humans.
To account for the attenuating affect of the aro mutation seen in mice, more importance was placed on the PABA dependence of these mutants (34) . Milhous et al. (35) reported that only low levels of PABA (1.0-10.0 nM) are present in human serum. Also, intracellular levels are probably lower or equally low as the serum PABA concentration in that mammals acquire the essential vitamin folate from their diet and mammalian cells do not possess the biochemical pathways or require the synthesis and utilization ofPABA for folate production (34) . Because the concentration of PABA normally present in mammalian tissue is minute, it has been assumed that, once within mammalian tissue, Salmonella aro mutants rapidly deplete their intracellular pool ofPABA and cease to grow, resulting in the observed attenuation of these strains in mice (11, 20) . In support of this thesis, Hoiseth (36) found that the virulence ofan S. typhimurium aro mutant in mice was significantly increased if the mice were maintained on water supplemented with 73 mM PABA, presumably as a result of increasing the serum PABA concentration.
We found that the growth rate ofaro mutant CVD 906 was not significantly decreased in minimal medium supplemented with as little as 5.0-10.0 nM PABA. Additionally, CVD 906 is capable of replicating (at reduced growth rates) in minimal media supplemented with minute concentrations ofPABA (between 0.05 and 5.0 nM). Thus, the concentration of PABA required to supplement the growth of CVD 906 is within the range reported in human serum (35) , and human serum PABA concentration may be sufficient to supplement the PABA requirement of CVD 906. Indeed, although CVD 906 does not replicate for more than a single generation in the complete absence of exogenous PABA, this candidate vaccine strain replicates for about nine generations in pooled human serum. Furthermore, addition of PABA to human serum did not increase the number of generations achieved by CVD 906 in human serum, suggesting that other factors limit the growth of CVD 906 in serum before exhaustion of PABA in this medium. As such the limited capacity of CVD 906 to replicate in human serum appears to be a consequence of the absence of other growth factors such as an iron chelator, orp-hydroxybenzoate.
The importance ofthe known siderophore defect in S. typhi aro mutants, an inability to synthesize enterochelin, in the attenuation of these mutants was thought to be minimal based on evidence from animal models (34). Benjamin et al. (37) showed that S. typhimurium ent mutants, which cannot synthesize enterochelin (an iron chelating catechol), retained full virulence in mice, and concluded that enterochelin is not a virulence factor ofS. typhimurium in mice. Ifin fact the inability to synthesize a siderophore such as enterochelin is the dominant growth-limiting factor in vivo that causes the attenuation of CVD 906 in humans, then this might indicate a difference between the phathogenesis of S. typhi in humans and the pathogenesis of S. typhimurium in mice. We are currently further investigating this question and how S. typhi aro mutants replicate intracellularly, where different growth conditions prevail.
CVD 906 underwent limited growth in individual sera derived from each of the volunteers, suggesting that growth-supplementing metabolites were present in the sera. Hence, growth in human serum per se does not completely explain the occurrence of occasional febrile responses after vaccination. The individuals who developed febrile adverse reactions to CVD 906 might have lower natural immunity (38) or greater sensitivity to S. typhi LPS-induced febrile responses (39, 40) or be influenced by genetic factors that otherwise increased their sensitivity to S. typhi (38) . Alternatively, the reactions caused by CVD 906 might be the result of special properties of this strain, whereas other S. typhi aro mutants may behave differently in volunteers. Possible further attenuation might derive from mutations that reduce growth rate in vitro (such as recA or cya-crp) (41, 42) , or mutations that diminish macrophage resistance (e.g., phoPQ, pag, prg, htrA, or groEL) (43-47). Increasing the phagocytic index of CVD 906 by introducing mutations that block Vi antigen synthesis (48, 49) , might also produce a further attenuated typhoid vaccine candidate. Vinegative strains have the added advantage ofbeing more sensitive to the bactericidal action of complement thus reducing their growth potential in the extracellular compartment (3, 50).
As a caveat, the clinical experience with CVD 906 once again highlights the limitations of animal models used for assessing Salmonella strains as noted earlier (3) . In calves, a transient increase in rectal temperature of 1.20C on average, was recorded -1 d after oral vaccination with 1.5 X 10 " cfu of S. typhimurium aro mutant strain SL326 1 (16); the calves regained normal body temperature and remained healthy without antibiotic or antipyretic treatment. On the other hand, in mice S. typhimurium aro mutant strain SL3261 is regarded as being safely attenuated ( 12) . Because death is used for the mouse typhoid model, in place of, not body temperature as the criterion of virulence, it is possible that a transient febrile response occurs after oral vaccination of mice with aro mutants ofS. typhimurium. In this perspective, the calfS. typhimurium model was more predictive of the outcome in humans. The mouse typhoid model might be improved, however, by including the measurement of body temperature along with lethalities, thereby including experimental criteria more relevant for human vaccine development. Also, in vitro assays such as were performed here provide helpful preclinical data by which attenuated S. typhi strains can be evaluated.
In previous clinical and field studies with attenuated S. typhi vaccine strain Ty2 la, the serum IgG 0 antibody response (measured by ELISA) was found to correlate with the protective efficacy ofdifferent immunization regimens as determined in large-scale field trials of vaccine efficacy (28). For this reason, the IgG-ELISA 0 antibody response has been used as a practical, helpful, and economical measure of the relative immunogenicity of candidate live oral typhoid vaccines. In this context, CVD 906 is impressively immunogenic when compared to previous live typhoid vaccines (4, 28, 29) . To further characterize the specificity of the S. typhi LPS responses, sera from the volunteers who ingested 5 x I0' CVD 906 bacilli were assayed for rises in IgG, IgM, and IgA specific for hot phenolpurified S. thompson LPS (0-antigen 6, 7; not shown). Two of the nine individuals manifested approximately fourfold rises in serum IgG specific for S. thompson LPS but there was no elevation ofIgM and IgA titers specific for S. thompson LPS. Therefore, the LPS responses shown here are highly specific for S. typhi O-antigen.
There were no significant rises in serum antibodies to the Vi antigen. This lack of responsiveness of the Vi component of live typhoid vaccines has been observed ( 51 ) . Also, responses to Vi antigen are uncommon after acute typhoid fever; rather, when high titers of antibody to Vi antigen are seen they are usually associated with the chronic typhoid carrier state (52) . In contrast, the Vi antigen, when purified and innoculated parenterally, is highly immunogenic (53) , indicating that the poor response to Vi antigen after vaccination with Vi-positive live typhoid vaccine strains might be the result oflow level or transient expression of this antigen in vivo.
Live oral attenuated S. typhi strains have potential as carriers of antigen from bacterial pathogens such as enterotoxigenic Escherichia coli (7) or Vibrio cholerae (54), or antigens from viral pathogens such as human immunodeficiency virus (T. Fouts, G. A. Lewis, and D. M. Hone, manuscript in preparation), which attach to, or enter the human host at intestinal mucosal sites. It follows that such live oral S. typhi vector vaccines must elicit effective intestinal secretory IgA responses. The ASC assay data presented here show that CVD 906 elicits high levels of intestinal priming of B cells (27, 55, 56) . In fact, the number of ASC detected by ELISPOT (> 2,000 ASC/ 106 PBMC) after immunization with 5 X I07 CVD 906 bacilli is an order of magnitude higher than the number normally seen after vaccination with multiple doses of live oral typhoid vaccine Ty2Ia (typically up to 100 ASC/ 106 PBMC) (55, 56) .
Although CVD 906 is reactogenic in humans at high doses, CVD 906 retains the important property of immunogenicity. We believe that only modest attenuation of this strain is required to produce a safe and highly immunogenic live oral typhoid vaccine and antigen carrier strain.
